TWEETIO
TWEETIO is a family of phenethylamine psychedelic drugs. They are analogues of the 2C drugs in which one or both of the methoxy groups at positions 2 and 5 of the phenyl ring have been lengthened to ethoxy groups. Examples include 2CD-2-ETO, 2CE-5-ETO, and 2CT2-5-ETO, among many others.
The TWEETIO drugs are said to have been named in a humorous way by pronouncing the simplest structural form of "2-EtO-X". Limited human data are available on the TWEETIO compounds. In any case, some generalizations have been made, including that the 2-ETO compounds tend to have a shorter duration and decreased potency, the 5-ETO drugs tend to have enhanced potency and remarkably increased durations, and the 2,5-Di-ETO drugs tend to be inactive.
The TWEETIO compounds were developed by Darrell Lemaire as potential "smart drugs" in the 1970s or 1980s. The compounds were described in the scientific literature by Alexander Shulgin via personal communication with Lemaire in the 1990s and 2000s. It was said by Shulgin in 2003 that the propoxy analogues had not yet been synthesized. In 2023, the propoxy derivative ASR-2001 was reported by Nick Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute. It is under development for potential medical use.
List and properties of TWEETIO drugs
also described some of these compounds in additional detail in his book PiHKAL.According to Shulgin in 2011, 2CB-5-EtO is not in the published scientific literature. In a 1994 literature review however, Shulgin described 2CB-5-EtO as being active but 2-fold less potent than 2C-B.
ASR-2001, a non-hallucinogenic TWEETIO analogue of 2C-B with a 5-propoxy group, is under development by the Alexander Shulgin Research Institute for use as a mild stimulant-like medication for the treatment of psychiatric disorders.
Another known TWEETIO-related drug, a 2C-E analogue with a 5-isopropoxy group, is 2CE-5iPrO.